Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs GDC 0084 (Primary)
- Indications Anaplastic astrocytoma; Glioma
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Oct 2018 to 1 Nov 2018.
- 15 Oct 2018 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 New trial record